Etanercept biosimilar now on PBS
A biosimilar version of etanercept has been listed on the PBS from 1 April.
Brenzys, MSD’s biosimilar answer to Pfizer’s Enbrel, is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis and non-radiographic spondyloarthritis.
Just as for the original biologic, authority is required and, depending on the indication, the patient must be being treated by a rheumatologist, clinical immunologist or dermatologist.
The biosimilar has been ‘a’ flagged, meaning that a pharmacist can offer the patient brand